305 related articles for article (PubMed ID: 19804390)
1. The safety of sumatriptan and naratriptan in pregnancy: what have we learned?
Cunnington M; Ephross S; Churchill P
Headache; 2009; 49(10):1414-22. PubMed ID: 19804390
[TBL] [Abstract][Full Text] [Related]
2. Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry.
Ephross SA; Sinclair SM
Headache; 2014; 54(7):1158-72. PubMed ID: 24805878
[TBL] [Abstract][Full Text] [Related]
3. Use of existing electronic health care databases to evaluate medication safety in pregnancy: Triptan exposure in pregnancy as a case study.
Yusuf A; Chia V; Xue F; Mikol DD; Bollinger L; Cangialose C
Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1309-1315. PubMed ID: 30240072
[TBL] [Abstract][Full Text] [Related]
4. Lamotrigine and the risk of malformations in pregnancy.
Cunnington M; Tennis P;
Neurology; 2005 Mar; 64(6):955-60. PubMed ID: 15781807
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results on pregnancy outcomes in women using lamotrigine.
Tennis P; Eldridge RR;
Epilepsia; 2002 Oct; 43(10):1161-7. PubMed ID: 12366730
[TBL] [Abstract][Full Text] [Related]
6. Triptan exposure during pregnancy and the risk of major congenital malformations and adverse pregnancy outcomes: results from the Norwegian Mother and Child Cohort Study.
Nezvalová-Henriksen K; Spigset O; Nordeng H
Headache; 2010 Apr; 50(4):563-75. PubMed ID: 20132339
[TBL] [Abstract][Full Text] [Related]
7. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment.
Reiff-Eldridge R; Heffner CR; Ephross SA; Tennis PS; White AD; Andrews EB
Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):159-63. PubMed ID: 10649172
[TBL] [Abstract][Full Text] [Related]
8. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy.
Namazy J; Cabana MD; Scheuerle AE; Thorp JM; Chen H; Carrigan G; Wang Y; Veith J; Andrews EB
J Allergy Clin Immunol; 2015 Feb; 135(2):407-12. PubMed ID: 25441639
[TBL] [Abstract][Full Text] [Related]
9. Birth Defects Among Fetuses and Infants of US Women With Evidence of Possible Zika Virus Infection During Pregnancy.
Honein MA; Dawson AL; Petersen EE; Jones AM; Lee EH; Yazdy MM; Ahmad N; Macdonald J; Evert N; Bingham A; Ellington SR; Shapiro-Mendoza CK; Oduyebo T; Fine AD; Brown CM; Sommer JN; Gupta J; Cavicchia P; Slavinski S; White JL; Owen SM; Petersen LR; Boyle C; Meaney-Delman D; Jamieson DJ;
JAMA; 2017 Jan; 317(1):59-68. PubMed ID: 27960197
[TBL] [Abstract][Full Text] [Related]
10. Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis.
Marchenko A; Etwel F; Olutunfese O; Nickel C; Koren G; Nulman I
Headache; 2015 Apr; 55(4):490-501. PubMed ID: 25644494
[TBL] [Abstract][Full Text] [Related]
11. Prenatal exposure to zidovudine and risk for ventricular septal defects and congenital heart defects: data from the Antiretroviral Pregnancy Registry.
Vannappagari V; Albano JD; Koram N; Tilson H; Scheuerle AE; Napier MD
Eur J Obstet Gynecol Reprod Biol; 2016 Feb; 197():6-10. PubMed ID: 26687320
[TBL] [Abstract][Full Text] [Related]
12. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy.
Pasternak B; Svanström H; Mølgaard-Nielsen D; Krause TG; Emborg HD; Melbye M; Hviid A
JAMA; 2012 Jul; 308(2):165-74. PubMed ID: 22782418
[TBL] [Abstract][Full Text] [Related]
13. Birth defects following exposure to efavirenz-based antiretroviral therapy during pregnancy: a study at a regional South African hospital.
Bera E; McCausland K; Nonkwelo R; Mgudlwa B; Chacko S; Majeke B
AIDS; 2010 Jan; 24(2):283-9. PubMed ID: 19864931
[TBL] [Abstract][Full Text] [Related]
14. Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study.
Spielmann K; Kayser A; Beck E; Meister R; Schaefer C
Cephalalgia; 2018 May; 38(6):1081-1092. PubMed ID: 28758416
[TBL] [Abstract][Full Text] [Related]
15. Naratriptan for the treatment of acute migraine: meta-analysis of randomised controlled trials.
Ashcroft DM; Millson D
Pharmacoepidemiol Drug Saf; 2004 Feb; 13(2):73-82. PubMed ID: 14998068
[TBL] [Abstract][Full Text] [Related]
16. Safety of sumatriptan in pregnancy: a review of the data so far.
Loder E
CNS Drugs; 2003; 17(1):1-7. PubMed ID: 12467489
[TBL] [Abstract][Full Text] [Related]
17. Safety of triptans for migraine headaches during pregnancy and breastfeeding.
Duong S; Bozzo P; Nordeng H; Einarson A
Can Fam Physician; 2010 Jun; 56(6):537-9. PubMed ID: 20547518
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of selected characteristics of pregnancy drug registries.
Honein MA; Paulozzi LJ; Cragan JD; Correa A
Teratology; 1999 Dec; 60(6):356-64. PubMed ID: 10590397
[TBL] [Abstract][Full Text] [Related]
19. First Trimester Influenza Vaccination and Risks for Major Structural Birth Defects in Offspring.
Kharbanda EO; Vazquez-Benitez G; Romitti PA; Naleway AL; Cheetham TC; Lipkind HS; Klein NP; Lee G; Jackson ML; Hambidge SJ; McCarthy N; DeStefano F; Nordin JD;
J Pediatr; 2017 Aug; 187():234-239.e4. PubMed ID: 28550954
[TBL] [Abstract][Full Text] [Related]
20. Use of 5-HT1 agonists in pregnancy.
Evans EW; Lorber KC
Ann Pharmacother; 2008 Apr; 42(4):543-9. PubMed ID: 18349309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
